Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Traumatic Brain Injury
Arun GuptaSmall moleculeEarly Phase 1Active
C
36/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 73/ 100
Competitive context
92 Active assets in the Traumatic Brain Injury cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MELATONIN Children's National Research Institute | Phase 4 | BBB |
Valproic Acid Northwestern University | Phase 4 | BBB |
PROPRANOLOL Tanta University | Phase 4 | BBB |
NEPENTHE Henry M. Jackson Foundation for the Advancement of Military Medicine | Phase 4 | BB |
N-Acetyl-L-Cysteine HonorHealth Research Institute | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →